Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine, in a randomized controlled trial, the benefits and costs of the American Heart Association's (AHA) advisory for depression screen and treatment of post-acute coronary syndrome patients.

Detailed Description
-----------------
Patients with an acute coronary syndrome (ACS) and comorbid depression have a 2-fold higher risk for recurrent ACS and mortality, worse quality of life, and higher costs of care than nondepressed ACS patients. The strength of these observational findings prompted the American Heart Association (AHA) to advise that routine depression screening for ACS patients and referral for depression diagnosis and treatment as indicated occur. Unfortunately, there are no randomized controlled trials (RCT) to inform this potentially expensive screening recommendation. Additionally, screening guidelines/advisories in the absence of RCT evidence have recently been extensively criticized (and withdrawn). This poses a serious dilemma for clinicians, health care systems, and for health care policy leaders. A RCT is urgently needed to provide evidence for these different constituents about the costs and benefits of the AHA depression screen and treat algorithm. Two critical gaps in knowledge must be filled to determine if public health would be improved by the AHA strategy for depression screening in post-ACS patients: 1) Does this strategy improve quality-adjusted life years for patients with a recent ACS 2) Is the cost of providing depression screening and any type of depression treatment within the acceptable and typical amounts reimbursed for health care services? Our specific aim is to determine the quality-adjusted life year benefits and health care costs of following the AHA's advisory for depression screening and then referral for further diagnosis and treatment in post-ACS patients, if depression is found. To accomplish this aim, we will randomize patients from four different, geographically diverse health care systems to three different groups: 1) to the AHA depression screen and treat if depression is found algorithm (screen and treat intervention group) or: 2) to be screened and a primary care provider notified (screen and notify intervention group) or: 3) to receive no depression screening (control group). Health-related quality of life, depressive symptoms, and costs will be obtained from all patients, so that the benefits and the costs of these three different depression screening strategies can be compared.

Official Title
-----------------
Depression Screening RCT in ACS Patients: Quality of Life and Cost Outcomes

Conditions
-----------------
Acute Coronary Syndrome, Depressive Symptoms

Intervention / Treatment
-----------------
* Other: Cognitive Behavioral Therapy (CBT)
* Drug: Antidepressant Medication
* Other: Standard Care
* Other: Depressive symptom screener
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With a documented acute coronary syndrome (ACS) within the past 2-12 months Over the age of 21 years Has access to a phone Exclusion Criteria: Medical Exclusions: Terminal illness (life expectancy <1 year as determined by physician/medical record) defined as, but not limited to: NYHA class IV, ACC class D CHF requiring inotropes or mechanical assist devices or critical aortic stenosis without plan for correction End-stage COPD/emphysema Advanced cirrhosis with encephalopathy, varices, severe ascites Severe rheumatologic diseases requiring frequent hospitalizations, and multiple cytotoxic agents and/or disease modifying drugs Metastatic pancreatic, esophageal, colorectal or stomach cancer Metastatic sarcoma, ovarian, melanoma or renal cell cancer Metastatic breast cancer with multiple recurrences despite treatment Advanced CNS malignancies Recurrent hematologic malignancies with multiple recurrences despite treatment Persistent AIDS, untreated or treated Psychiatric Exclusions: History of major depression Currently receiving depression treatment Dementia History of bipolar disorder History of psychosis History of suicide attempt or self-inflicted injuries Current alcohol or substance abuse Other Exclusions: Non-English and non-Spanish speaking

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AHA Depression Screen & Treat<br>Participants randomized to this arm will complete the Depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will be offered treatment. Treatment will be delivered according to participant preference, and will be managed according to stepped care. Stepped care includes, a) participant preference for either brief, cognitive behavioral therapy (CBT), delivered centrally by telephone, or antidepressant medication managed at the local site, or both, or neither, and b) review of progress at approximately 2-month intervals, with stepping up of care if sufficient progress is not being realized. | Other: Cognitive Behavioral Therapy (CBT)<br>* The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment. CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement .<br>* Other names: Problem Solving Therapy (PST);Drug: Antidepressant Medication<br>* The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment. Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated.<br>* Other names: Bupropion;Other: Depressive symptom screener<br>* 8-item Patient Health Questionnaire, PHQ-8<br>* Other names: PHQ-8;|
| Active Comparator: Depression Screen & Notify Arm Type :<br>Participants randomized to this arm will complete the depressive symptom screener (8-item Patient Health Questionnaire, PHQ-8) after randomization. Those with clinically significant score (>=10) will have a letter sent to their primary care provider about their positive screen for depressive symptoms, with subsequent actions at the provider's discretion. | Other: Standard Care<br>* Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.<br>Other: Depressive symptom screener<br>* 8-item Patient Health Questionnaire, PHQ-8<br>* Other names: PHQ-8;|
| Placebo Comparator: No Depression Screen<br>Participants randomized to this arm will not complete a PHQ-8 assessment at randomization, and so will not be screened for depressive symptoms. | Other: No intervention<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality-Adjusted Life Years (QALYs) | Change in QALYs from baseline through 18 months. QALYs are a generic measure of disease burden, including both the quality and the quantity of life lived. One QALY equates to one year in perfect health. To measure change in QALYs, utility scores [an overall assessment of well-being on a scale from 0 (death) to 1 (perfect health)], were estimated using the Short Form-6 dimension, with scores derived from responses to the 12-Item Short-Form Health Survey, version 2, at baseline and 6, 12, and 18 months. QALYs for the period from baseline to 18 months were then calculated as the area under the curve by linearly interpolating the utility scores at the 4 assessments. Change in QALYs was then obtained by subtracting the baseline QALY from the observed QALY for an 18-month period, where baseline QALY was calculated under the assumption that the baseline utility score remained constant during the 18-month period. | Baseline, 6, 12 and 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Depression-free Days | Depression-free days from baseline through 18 months post-randomization | Baseline through 18 months | 
| Cost of Health Care Utilization | Total cost of health care utilization from baseline through 18 months post-randomization | Baseline through 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Coronary Syndrome, Depressive Symptoms